Your session is about to expire
← Back to Search
Semaglutide for Alcoholism
Study Summary
This trial is testing if a medication (Semaglutide) can reduce drinking in adults with Alcohol Use Disorder (AUD). Participants will visit NIDA in Baltimore for ~5 months, take tests, and receive weekly shots.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does my profile fit the criteria for enrolment in this research program?
"To be suitable for this research, participants must have an alcohol addiction and be between 18 and 110 years old. The study intends to enrol a total of 52 individuals."
What potential hazards are associated with taking Semaglutide?
"According to our assessment, semaglutide has a safety rating of 2. This is because it is still in phase 2 trials and there's only evidence supporting its security profile but no data that confirms the efficacy of this medication yet."
Does this experiment facilitate the inclusion of senior citizens?
"This trial necessitates that enrollees are aged between 18 and 110. The same clinical study also has 21 sub-trials for those under the legal age of consent, as well as 229 trials specifically designed for seniors over 65 years old."
Is enrollment currently available for this trial?
"Clinicaltrials.gov attests to the fact that recruitment for this research endeavour is ongoing. The trial was launched on December 1st 2023 and its most recent update occurred on September 22nd of the same year."
What is the size of the cohort participating in this clinical trial?
"Affirmative. Clinicaltrials.gov provides information that recruitment for this medical trial has begun, with the initial posting occurring on December 1st 2023 and an update happening on September 22nd of the same year. Currently, 52 patients need to be recruited from a single clinical site."
What is the aim of this clinical experiment?
"This trial's primary outcome is to be assessed by the variance in standard alcohol-containing drinks consumed per week between baseline and study end. Further, investigators will evaluate whether semaglutide can reduce blood Phosphatidylethanol (PEth) levels as a biomarker of alcohol use, decrease cravings triggered by cues typically encountered at bars via craving scores, and alter food choices made in virtual reality buffet scenarios."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger